Mr. Creaturo has 20 years of experience in the pharmaceutical industry specializing in venture acquisition management and new technology commercialization. In the past 15 years, Mr. Creaturo was responsible for the management of companies that successfully commercialized key processes and compounds used in the world's top three drugs.
Dr. Zuhse currently serves in capacity as CSO as well as President of Chiracon GmbH a sister company specializing in Chiral technologies and small molecule development. He holds a PhD in Organic Synthesis and will integrate some of Chiracon's world class chiral technologies to increase efficacy and lower side effects of key anti-Infective and oncology therapeutic drugs of Asepsis Pharmaceuticals. Dr. Zuhse holds patents for his specialty processes for fermented cytotoxic antibiotics.
Dr. Villatoro joins Asepsis as Chief Medical Officer. Dr. Villatoro holds an M.D. degree in Medicine from the Instituto Politécnico Nacional at Mexico City. Dr. Villatoro specializes in Pediatrics, Diabetes and Infectious Disease. Dr. Villatoro will focus his R&D efforts on the evaluation of emerging disease threats in under served markets, including how Asepsis's proprietary delivery devices can be integrated to develop more effective treatments for these diseases, leading to improved patient outcomes.
Mr. Siddharth joins Asepsis with the responsibilities of overseeing all operational activities of Asepsis, (India). He has 18 years of experience in the pharmaceutical industry specializing in outsource production, acquisitions and new venture project management. He has been directly responsible for various fortune 50 companies establishing facilities and joint ventures within India over the last decade.